Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Marketing Status Prescription
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 60505-6119; 42023-229; 42023-230; 60505-6120
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000184%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.000705%Not Available
Chills15.05.03.016; 08.01.09.0010.000184%
Cholestasis09.01.01.001--Not Available
Coagulopathy01.01.02.0010.000705%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.002--
Death08.04.01.0010.003310%
Decubitus ulcer23.03.11.006--Not Available
Delirium19.13.02.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Drug level increased13.17.01.004--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.0020.001762%
Encephalopathy17.13.02.001--
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.001--
Epistaxis22.04.03.001; 24.07.01.0050.001762%
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.004--
Feeling abnormal08.01.09.014--Not Available
Fluid overload14.05.06.001; 02.05.04.004--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages